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Abstract
Background: Disease-modification clinical trials in neurodegenerative disorders have struggled to separate
symptomatic effects of putative agents from disease-modification. In response, a variety of clinical trial designs have
been developed. A systematic review was undertaken to examine which trial designs have been used in
Alzheimer’s disease (AD) and Parkinson’s disease (PD) to detect disease-modifying, as opposed to symptomatic,
drug effects. In addition we aimed to identify novel clinical trial designs used in the past or planned for use in the
future. We aimed to critique whether the methods used would have identified true disease-modification.
Methods: MEDLINE, Embase and CENTRAL (1980–2015) were searched to identify papers meriting review in full.
ClinicalTrials.gov was searched to identify unpublished or planned randomised controlled trials (RCTs). We included
RCTs in PD or AD which aimed to demonstrate the disease-modifying properties of drug therapy and differentiate
that benefit from any symptomatic effect.
Results: 128 RCTs were finally included: 84 in AD (59 published, 25 unpublished); 44 in PD (36 published, 8
unpublished). A variety of clinical trial designs were applied including long-term follow-up, wash-in and wash-out
analyses, randomised delayed-start, the use of time-to-event outcome measures and surrogate disease progression
biomarkers. Deficiencies in each of these design strategies, the quantity of missing data in included RCTs and the
methods used to deal with missing data, meant that none of the included studies convincingly demonstrated
disease-modification. No truly novel clinical trial designs were identified.
Conclusion: We currently believe that the best clinical trial design available to demonstrate disease-modification is
a long-term follow-up study, in which an examination is made for sustained divergence in outcome measures
between treatment arms over the study period.
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Background
Despite extensive research in neurodegenerative dis-
eases, drugs which halt, or even slow, neurodegeneration
and, therefore, clinical progression remains elusive.
Whilst this failure probably in part reflects our incom-
plete understanding of the complex pathophysiology of
neurodegenerative disorders, it also relates to difficulties
in designing clinical trials to develop new disease-
modifying agents.
Clinical trials in neurodegenerative disorders, including
the two commonest disorders Parkinson’s disease (PD)
and Alzheimer’s disease (AD), have struggled to find ways
to separate out symptomatic effects of potential agents
(e.g. due to increased striatal dopamine in PD, or
increased acetylcholine in AD) from disease-modifying ef-
fects. Clinical assessments (e.g. in PD using motor, disabil-
ity or quality of life scales) are affected/confounded by
symptomatic effects of therapy and are unable to differen-
tiate this effect from disease-modification, at least in the
short-term. Researchers have, therefore, used surrogate
biomarkers for disease progression (on the basis that they
may be ‘immune’ to symptomatic drug effects) as the out-
come measure in disease-modification trials. However, as
our previous systematic reviews of biomarkers for disease
progression in AD [1] and PD [2] found, there is currently
insufficient evidence to recommend the use of any bio-
marker for disease progression as an outcome measure in
disease-modification trials. Various clinical trial designs
have also been developed to try to adjust for the symp-
tomatic effects of putative disease-modifying agents and,
therefore, allow clinical rating scales to be used as end-
points. These include measuring outcomes following a
wash-out period [3, 4], delayed-start trial design [5], and
long-term follow-up studies of placebo-treated and active-
agent treated subjects.
Whilst the results of disease-modification clinical
trials in PD, but not to our knowledge in AD, have
been reviewed systematically [6], no previous attempt
has been made to systematically review the trial de-
signs used in such randomised controlled trials
(RCTs) to separate out disease-modifying effects of
putative agents from symptomatic effects. Such a re-
view could demonstrate which (if any) of the well de-
scribed advanced clinical trial designs is most
effective, and highlight novel trial designs which have
been successfully applied in the past or are planned
for use in the near future.
We, therefore, undertook a systematic review to deter-
mine which trial designs have been used in AD and PD
to detect disease-modifying, as opposed to symptomatic,
drug effects. In addition we aimed to identify any novel
clinical trial designs used in the past or planned for use
in the future. We aimed to critique whether the methods
used would have identified true disease-modification.
Methods
As this study was a systematic review ethical approval
was not required. Literature searches were conducted in
the databases MEDLINE (1980 to September 2015),
Embase (1980 to September 2015) and the Cochrane
Central Register of Controlled Trials (CENTRAL)
(searched September 2015) using the OVID search inter-
face. Text words and index headings for AD and PD
were combined with similar terms for neuroprotection
and disease-modification. To help identify RCTs in
MEDLINE and Embase the search outcome was then
combined with the Cochrane Highly Sensitive Search
Strategy for identifying RCTs in MEDLINE [7] and with
search terms used by the UK Cochrane Centre for
searching Embase for RCTs [8], respectively. Further-
more, in an attempt to identify completed RCTs which
remained unpublished at the time of this review and those
which were planned or in progress, we also searched the
ClinicalTrials.gov database (searched September 2015)
using their website (http://www.ClinicalTrials.gov/).
Details of the electronic search strategy are given in
Additional file 1.
Reference lists of relevant review articles and finally
included articles were also checked to identify any stud-
ies which the electronic search strategy may have
missed. We tried to identify and source publications re-
lated to relevant trials registered with ClinicalTrials.gov.
We used Google to identify websites and press releases
related to unpublished trials.
Study selection
The two-stage selection procedure was performed by a
single reviewer. In the first stage article titles and ab-
stracts retrieved by the electronic search were reviewed
to determine which articles merited review in full. Full
length articles, where available, were then reviewed be-
fore data were extracted from relevant papers. In both
stages the inclusion and exclusion criteria detailed below
were applied.
Study design
We included RCTs in AD or PD which tried to dem-
onstrate the disease-modifying properties of any form
of drug therapy and differentiate that benefit from
any symptomatic effect. Unfortunately, many studies
whose aim was clearly to demonstrate disease-modification
(as revealed by the methodology, discussion and conclu-
sions) failed to state this explicitly. Therefore, to ensure we
did not miss studies with potentially important clinical trial
designs we included all studies where the main thrust of
the article appeared to be the demonstration of disease-
modification. In doing so we were aware that we risked be-
ing overly inclusive, but as we aimed to critique the clinical
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trial designs rather than meta-analyse the study results we
did not feel this was a major problem.
Trial participants must have been followed-up for a
period of at least 6 months during which they were ex-
posed to the active-agent or placebo. We felt it highly
unlikely that disease-modification could be demon-
strated in a period of less than 6 months, although even
this time period may be too short.
As one of the aims of this review was to identify novel
clinical trial designs planned for use in the future, we in-
cluded both published and unpublished RCTs. Unpub-
lished RCTs were included to reduce the potential
publication bias associated with null findings. For the
purposes of this review, where sufficient information re-
garding a trial was available from a conference abstract
or a pharmaceutical company press release then that
trial was considered to be published. For each RCT with
several publications we identified the most informative
paper which corresponded to the main pre-specified
study analysis. We, therefore, did not include extension
phases to RCTs unless these were clearly pre-specified.
There was no language restriction for this review.
Population
RCTs were only included where all participants had a
diagnosis of probable AD (made using formal research
criteria) or PD (made using formal research criteria or
on clinical grounds). Studies which included participants
with prodromal AD or mild cognitive impairment (MCI)
were only included if conversion from MCI to AD was
confirmed in all participants by clinical follow-up. We
made no restriction on the grounds of participants’ age,
disease duration, disease severity, or drug treatment.
Intervention
We restricted our systematic review to RCTs of non-
invasive drug therapy. Trials testing intraventricular or
intrathecal treatments, foetal or embryonic stem cells,
striatal delivery of growth factors, or deep brain stimula-
tion were excluded.
Comparison/Outcomes/Setting
We made no restriction based on the type of compari-
son group(s) or outcome measure(s) used in RCTs, or
the trial setting.
Data extraction
Study methods and results were extracted by a single
reviewer, and to check for accuracy this was per-
formed twice. Data were extracted using an extraction
sheet (see Additional file 2) relating to the following: (1)
year of publication and study location; (2) study popula-
tion, including number of participants, their age, baseline
measures of disease severity and baseline treatment status;
(3) details of the putative agent under investigation, in-
cluding its suspected mechanism of action; (4) study out-
comes, including details of the primary outcome measures
and any biomarkers or time-to-event outcomes used as
secondary outcome measures; (5) trial design, including
methods used to differentiate disease-modifying from
symptomatic effects of the putative agent, methods used
to deal with deaths and drop-outs in statistical analyses,
and the pre-defined trial length; (6) study results, includ-
ing the percentage of participants who completed the
pre-defined follow-up period, reached the trial end-
point, and were included in the primary analyses; and
(7) study conclusions, including whether the study in-
vestigators felt disease-modification had been demon-
strated and if their conclusions were backed up by
the trial methodology and results.
In this review the term ‘long-term follow-up’ was ap-
plied to studies that: (1) formally examined for sustained
divergence in outcome measures between groups over
time (i.e. through slope analyses); (2) did not formally
measure sustained divergence but published figures (e.g.
Kaplan Meier plots) from which the presence or absence
of sustained divergence could be inferred; or (3) used no
alternative design strategy to try to demonstrate disease-
modification.
Methodological quality
We did not formally assess study quality in terms of
methods to reduce bias (e.g. methods of generating and
concealing the randomisation sequence, blinding, source
of funding) in this review as our primary aim was to
examine what clinical trial designs have been used or are
planned in RCTs to demonstrate disease-modification.
However, we did examine losses to follow-up and how
this was dealt with as this would clearly impact on inter-
pretation of whether a given treatment had disease-
modifying properties.
Data analysis and synthesis
Given the descriptive nature of this systematic review
extracted data was narratively synthesised. The number
of participants randomised into RCTs in AD and PD
was compared using the Mann–Whitney test.
Results
Data were extracted from a total of 128 RCTs: 84 involv-
ing participants with AD and 44 participants with PD
(Fig. 1). At the time of undertaking this review, 70 and
82 % respectively of included RCTs in AD and PD were
completed and published. The reasons for exclusion of
full-text articles are also detailed in Fig. 1, the most
common being that the article was a less informative
write-up or interim analysis of an already included RCT.
Four futility studies were excluded [9–12] because,
McGhee et al. BMC Neurology  (2016) 16:92 Page 3 of 13
whilst these may have a preliminary role in the develop-
ment of disease-modifying agents, they do not aim to
differentiate disease-modifying effects of putative agents
from symptomatic effects. Rather they aim to determine
whether or not putative agents have any efficacy and,
therefore, merit further investigation.
Additional files 3 and 4 detail the compounds investi-
gated for disease-modifying potential in the included
published RCTs in AD and PD, respectively. These tables
also outline the characteristics of participants at the time
of entry into each of the studies. Similarly, the details of
RCTs in AD and PD which were completed but remained
unpublished, were ongoing, or were yet to commence, are
given in Additional files 5 and 6, respectively.
Pharmaceutical agents reputed to have anti-amyloid or
anti-inflammatory properties were most commonly ex-
amined in AD RCTs, whereas in PD antioxidants were
most frequently examined. The majority of studies in
both disorders were conducted in centres in North
America and Europe. The median pre-specified length of
RCTs included  
in final analysis  
(n = 128)
Full-text articles excluded  
(n = 206) 
RCT without clear aim of demonstrating 
disease-modification (50) 
Post-hoc analysis of ≥ 1 RCTs (34) 
Less informative write-up or interim 
analysis of included RCT (58) 
Not a RCT (18) 
Extension of a RCT (14) 
Period of follow-up < 6 months (14) 
Patients without Alzheimer’s disease or 
Parkinson’s disease included (9) 
Futility trial (4) 
Insufficient information to include (3) 
RCT of physical therapy (1) 
Sub-study of an included study (1) 
Full-text articles 
assessed for eligibility  
(n = 334)
Records excluded on 
screening  
(n =3157)Records screened  
(n = 3531)
Records after duplicates removed  
(n = 3425)
Additional records identified by reviewing 
reference lists or by searching for the 
published version of a trial registered on 
Clinicaltrials.gov  
(n = 106)
Records identified by database 
searches: MEDLINE, Embase 
and CENTRAL (1980 - Sep 
2015), and ClinicalTrials.gov  
(n = 4139)
Records excluded as 
review article  
(n = 40)
Alzheimer’s disease 
RCTs  
(n = 84)
Parkinson’s disease 
RCTs  
(n = 44)
PDPublished (36)
PDUnpublished (8)
ADPublished (59)
ADUnpublished (25)
Fig. 1 Flow diagram outlining the selection procedure to identify the 128 finally included randomised-controlled trials (RCTs)
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follow-up in the RCTs in AD was 12 (interquartile
range (IQR) 6 to 18) months, and in PD 16 (IQR 12
to 24) months. However, these figures do not include
trials in which the length of planned follow-up was
defined as being until all participants reached a spe-
cific end-point (e.g. until all participants with PD
required levodopa).
Characteristics of participants
The total number of participants randomised in the
completed RCTs in AD was 24,173 and in PD 10,652.
Although the median number randomised in the AD
RCTs was higher (median 313 (IQR 91 to 581)) than in
the PD RCTs (median 111 (IQR 54 to 393)), this differ-
ence was not statistically significant (P = 0.06).
The mean age of participants in the AD RCTs was
73.4 (standard deviation (SD) 2.9) years. The vast ma-
jority of participants with AD were on symptomatic
treatment at the time of study entry. Indeed, several
studies stipulated that subjects had to be on treat-
ment or commence treatment with a pre-specified
cognitive enhancer to qualify for study entry. This
was justified as a way of reducing the confounding
effects of symptomatic treatments patients may other-
wise have required during the course of the study.
Disease severity scores indicated that participants in
the AD RCTs had mild to moderate disease (median
Mini-Mental State Examination [13] (MMSE) 20 (IQR
19 to 21), median Alzheimer’s Disease Assessment
Scale – cognitive subscale [14] (ADAS-cog) 24 (IQR
22 to 26), median Washington University Clinical De-
mentia Rating Sum-of-Boxes score [15] (CDR-SB) 5.7
(IQR 5.3 to 5.9)).
Participants in the PD RCTs were fairly young (mean
age 61.9 (SD 1.6) years). Unlike the AD RCTs, the
majority of participants in the PD RCTs were not on
symptomatic treatment at baseline. Many studies
stipulated that participants had to be drug naïve to
qualify for study entry. This stipulation was made to
avoid the confounding effects of symptomatic treat-
ment or because the time until symptomatic treatment
was required was an outcome measure for the study. In
one study [16], only fluctuating patients on symptom-
atic treatment were included and assessments were
made in a practically defined off phase after 12–24 h
drug withdrawal. As might be expected for disease-
modification RCTs, those randomised into the PD
RCTs had mild to moderate disease (median Hoehn
and Yahr staging scale [17] (H&Y) 1.7 (IQR 1.5 to 1.9),
median total score derived from the Unified Parkinson’s
Disease Rating Scale [18] (UPDRS) 25 (IQR 21 to 29),
median motor component of the Unified Parkinson’s
Disease Rating Scale (UPDRS (III)) 18 (IQR 16 to 21)).
Clinical trial designs used to demonstrate disease-
modification
A summary of the methods used in an attempt to dem-
onstrate the disease-modifying potential of pharmaceut-
ical agents in the RCTs included in this review is
presented in Table 1 and in more detail in Additional
files 7 (AD) and 8 (PD).
In the majority of included AD RCTs more than one
design strategy was used to try to demonstrate disease
modification. Long-term follow-up was most frequently
used (n = 45/59 (76 %) of included published AD
studies). However, an attempt to undertake slope ana-
lyses to formally demonstrate sustained divergence was
only made in one AD study designated as a long-term
follow-up study in this review [19]. Trials examining the
disease-modifying properties of anti-inflammatory agents
(e.g. ibuprofen) most commonly did not employ an alter-
native design strategy. They appeared to rely on the as-
sumption that such agents have no symptomatic effects
and, therefore, any difference in primary and secondary
Table 1 Trial designs used in included randomised controlled trials to try to demonstrate disease-modification
Type of trials Wash-in
analysis
Wash-
out
analysis
Delayed-
start trial
design
Long-
term
follow-
up
Biomarkers
(primary or secondary outcome measures)
Time-to-
event
outcomesImaging CSF Blood Other
n % n % n % n % n % n % n % n % n %
AD Published (n = 59) 3 5 11 19 7 12 45 76 27 46 17 29 6 10 2 3 3 5
Planned, ongoing &
unpublished (n = 25)
0 0 0 0 2 8 22 88 12 48 10 40 4 16 0 0 1 4
All (n = 84) 3 4 11 13 9 11 67 80 39 46 27 32 10 12 2 3 4 5
PD Published (n = 36) 11 31 17 47 7 19 25 69 12 33 0 0 1 3 0 0 18 50
Planned, ongoing &
unpublished (n = 8)
0 0 3 38 0 0 4 50 4 50 1 13 0 0 0 0 3 38
All (n = 44) 11 25 20 45 7 16 29 66 16 36 1 2 1 2 0 0 21 48
(CSF Cerebrospinal fluid. ‘Other’ biomarkers include a urine biomarker and electroencephalography used in published AD trials)
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clinical outcome measures between treatment groups
after follow-up must be due to disease-modification.
Biomarkers of disease progression, most notably brain
imaging (n = 39/84 (46 %) of included AD RCTs) and
cerebrospinal fluid (CSF) biomarkers (n = 27/84, 32 %),
were also frequently used as primary or secondary out-
come measures to demonstrate disease-modification. In
eleven AD studies (13 %) a wash-out analysis [3, 4] was
employed to try to demonstrate disease-modification,
and in three studies (4 %) a wash-in analysis [3] was
used to try to show the absence of an early symptomatic
effect. A randomised delayed-start design [5] was used
in nine (11 %) included AD RCTs.
The most commonly used design strategy to demon-
strate disease-modification in the RCTs in PD was a
wash-out analysis (n = 20/44 (45 %) of included studies).
There was, however, variability in how data relating to
wash-out periods were analysed. Most frequently an
examination was made for a statistically significant de-
terioration during the wash-out period in pre-specified
clinical outcome measures in those treated with the
active-agent. Additionally, in some cases, statistical tech-
niques were used to determine whether any deterior-
ation observed during the wash-out period in the active-
agent treated group was greater than that observed in
the placebo-treated group. Generally in these analyses
the lack of significant deterioration in the active-agent
treated group during the wash-out period, or deterior-
ation not significantly greater than that observed in the
placebo-treated group, was interpreted as meaning that
any beneficial effect of the active-agent over placebo
during the trial arose from disease-modification rather
than a symptomatic effect. In other studies the primary
efficacy analysis was conducted from baseline until the
end of the wash-out period with the assumption that
any observed beneficial effect of the active-agent over
placebo must have been due to disease-modification. In
one study of lazabemide [20], a blinded staggered with-
drawal of lazabemide after either 52 or 54 weeks of
treatment was undertaken. This was followed respect-
ively by placebo for either 4 or 2 weeks. The authors
stated that this staggered withdrawal was designed to
allow ‘a more objective assessment of the effects of dis-
continuing experimental treatments’. However, the ad-
vantages of undertaking this more complicated wash-out
analysis are not entirely clear.
Wash-in analyses aimed at demonstrating the ab-
sence of an early symptomatic effect of a putative
agent and, thereby, providing support to assertions of
a disease-modifying effect drawn from other design
strategies, were employed in eleven (25 %) of the PD
RCTs. In seven PD trials (16 %) a randomised
delayed-start design was used, with the length of
delay ranging from 6 to 9 months.
Imaging biomarkers for disease progression, namely
PET and SPECT brain imaging, were used or planned
for use to try to elicit a disease-modifying effect in 16
(36 %) PD RCTs. Only two trials (5 %) used or
planned to use a biomarker modality other than brain
imaging.
Twenty-five (69 %) of the 36 included published PD
RCTs were classified as long-term follow-up studies in
this review. Of these, however, only one undertook for-
mal slope analyses to try to demonstrate sustained diver-
gence in outcome measures between groups over time
[21]. In a further 20 (56 %) published PD RCTs figures
were provided which allowed the presence of sustained
divergence in outcome measures between groups over
time to be interpreted to some degree.
Trial outcome measures
Additional files 9 and 10 detail the outcome measures
and methods used to deal with missing data in the com-
pleted RCTs in AD and PD, respectively, in addition to
providing more detailed information about the methods
used to try to detect disease-modification. Similar infor-
mation regarding the ongoing, planned or unpublished
RCTs is given in Additional files 5 and 6.
As Table 2 displays, the majority of RCTs in AD and
PD used a clinical rating scale to define their primary
outcome. These trials, therefore, relied either on their
design strategy or on the assumption that the putative
agent had no symptomatic effects to demonstrate
disease-modification.
Only three RCTs in AD employed a time-to-event out-
come as their primary outcome measure [22–24], al-
though another did use such a measure as a secondary
outcome [25]. The time-to-event outcome measures
used in AD trials related either to a specific level of clin-
ical worsening, hospitalisation, institutionalisation or
death.
The use of time-to-event outcome measures in PD
RCTs was commoner, with 11 trials using such a me-
asure as a primary outcome and ten as a secondary out-
come. Most frequently the chosen time-to-event
outcome was the time until levodopa or dopaminergic
treatment was required on the basis of an individual
patient’s level of disability. This outcome was, there-
fore, used as a surrogate measure of disability. In
RCTs which used this outcome measure a wash-out
analysis was often undertaken after reaching the study
termination point (i.e. need to commence levodopa)
to try to demonstrate the absence of a symptomatic
effect on secondary clinical outcome measures and,
therefore, prove that any beneficial effect on the
time-to-event primary outcome measure was due to
disease-modification.
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Methods used to deal with missing data
Additional files 11 and 12 detail the percentage of partic-
ipants enrolled at baseline in each completed RCT in
AD and PD who (if applicable) completed the pre-
defined follow-up period, reached the trial endpoint, and
were included in analyses of the primary outcome meas-
ure. In addition, the authors’ interpretation of the study
results in terms of whether or not disease-modification
was demonstrated is given in these additional files.
In the published RCTs in AD and PD the median per-
centage of participants who completed the double-blind
treatment periods were 74 % (IQR 64 to 78) and 73 %
(50 to 84), respectively. Of the ten published PD RCTs
in which the primary outcome was defined by a time-to-
event outcome a median of 64 % (40 to 83) of partici-
pants reached that outcome before the study terminated.
In one of the three trials in AD where the primary out-
come was defined by a time-to-event outcome (the time
until clinically significant agitation or psychosis) only
17 % of participants enrolled at baseline reached that
endpoint before the study ended [23].
Despite the above figures, the use of various methods
to deal with missing primary outcome data, as sum-
marised in Table 3, meant that 88 % (SD 14 %) of partic-
ipants enrolled at baseline in the AD RCTs and 85 %
(SD 17 %) in the PD RCTs were included in analyses of
primary outcome data in these trials. Methods used in-
cluded; complete-case analysis, in which only data from
those who completed a trial and have complete data for
a given variable are included; last observation carried
forward (LOCF), in which missing data points for partic-
ipants not completing a trial are replaced by the last ob-
served value for that variable; and data imputation
where missing data points are replaced by substituted
values. Mixed models were more commonly used in
RCTs in AD than in PD, probably reflecting the more
frequent use of survival analysis in PD trials, which often
employed time-to-event primary outcome measures. It is
worth noting that only 36 (61 %) of the published RCTs
in AD and 19 (53 %) in PD stated that they applied an
intention-to-treat (ITT) approach to their statistical
analyses.
Trial results
In 21 (36 %) published RCTs in AD and 17 (47 %) in PD
the authors concluded that their analyses provided evi-
dence of possible or probable disease-modifying proper-
ties (at least in some subgroups) of the agent under
investigation. However, for reasons which will be dis-
cussed further below, we feel that none of these trials
definitely proved that a putative agent had disease-
Table 2 Types of primary outcome measures used in all included randomised controlled trials
Primary outcome measure Frequency of use of primary outcome measure in randomised controlled trials in:
Alzheimer’s disease
(n = 83)
Parkinson’s disease (n = 44)
n % n %
Clinical outcome measure only 62 75 24 55
Clinical outcome measure and
biomarker
6 7 4 9
Clinical outcome measure and
time-to-event outcome
1 1 0 0
Biomarker only 12 15 5 11
Time-to-event outcome only 2 2 11 25
There was insufficient information available about one unpublished trial’s [42] outcome measures to allow its classification
Table 3 Methods used to deal with missing primary outcome data in included published randomised controlled trials
Method used to deal with
missing data
Frequency of use in RCTs in:
Alzheimer’s disease
(n = 47)
Parkinson’s disease (n = 31)
n % n %
Complete-case analysis 14 30 11 35
Survival analysis 3 6 10 32
Last observation carried forward 16 34 6 19
Mixed model 18 38 4 13
Data imputation 7 15 4 13
Twelve AD trials did not report any information regarding how missing data was dealt with, four used two methods and two used three methods and one used
four methods. Five Parkinson’s disease trials did not report any information regarding how missing data was dealt with and four used two methods
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modifying properties as opposed to simply symptomatic
benefits.
Discussion
This systematic review demonstrated that RCTs in
AD and PD have used a variety of design strategies
(i.e. wash-in and wash-out analyses, delayed-start de-
signs, long-term follow-up with examination for sus-
tained divergence in outcome measures, including
time-to-event outcomes, between groups over time)
either alone, in combination with one another or in
conjunction with a biomarker, to try to demonstrate
the disease-modifying properties of therapeutic agents
over any symptomatic effect.
In the RCTs included in this review we found little evi-
dence of novel clinical trial designs having been used in
the past or planned for use in the future. Perhaps of
most interest was the pragmatic approach recently used
in a non-placebo controlled parallel group study of exe-
natide, an injectable drug approved for the treatment of
diabetes, in PD [16]. By repurposing a drug to treat a
novel disease development cost and time may be re-
duced. In this trial participants were assessed after
overnight withdrawal of conventional PD medications
(PD medications were allowed to reduce attrition) using
blinded video assessment after a 2-month wash-out
period off the study drug. The study demonstrated that
those receiving exenatide improved over 14 months
while those not receiving it declined. Whilst this finding
could represent a prolonged symptomatic effect or, less
likely, a protracted placebo effect, it does signal some
possible efficacy in a cost-effective manner which may
be worth pursuing in a more expensive double-blind,
placebo-controlled trial.
On the basis of their trial results many authors con-
cluded that the drug they had investigated had possible
or probable disease-modifying properties. However,
given the flaws in the study designs used, and problems
with how missing data was handled, we feel that no
study demonstrated true disease-modification. We will,
therefore, discuss the merits of each design strategy in
turn and outline our concerns as to how missing data
was dealt with.
Wash-in analysis
A wash-in analysis [3] compares the change between
groups in clinical outcome measures over the first
few weeks or months of a study. Greater improve-
ment in active-agent than placebo-treated subjects is
interpreted as indicating an early symptomatic effect,
the assumption being (probably rightly) that a true
disease-modifying effect would not be seen so soon:
disease progression over such a short period of time
would probably be minimal.
In general, wash-in analyses were used to try to dem-
onstrate that a symptomatic effect was not associated
with a given putative agent, rather than prove disease-
modification in isolation. Wash-in analyses were gener-
ally combined with other design strategies (e.g. wash-out
analyses) to provide additional support to claims that a
given agent lacked a symptomatic effect. The conclusion
then often drawn was that any difference in the primary
outcome measure between groups at the end of the
study must be due to disease-modification.
Wash-out analysis
In a wash-out analysis [3, 4] treatment is withdrawn
from both the active-agent and placebo-treated groups
at the end of the study. The active-agent is assumed to
have disease-modifying properties if those treated with it
show slower disease progression throughout the double-
blind treatment period than those treated with placebo,
and less severe deterioration when treatment is with-
drawn. However, there are a number of problems with
this study design and the way in which it was employed
in some of the included RCTs.
Firstly, it can be difficult to withdraw medications
from patients as their symptoms may rapidly relapse and
lead to their withdrawal from the trial. In wash-out ana-
lyses it is not clear how to deal with missing data from
patients who withdraw during wash-out. If the data of
those who withdraw is censored then analyses risk being
biased in favour of those who did not experience a
significant clinical deterioration following treatment
withdrawal. A symptomatic effect could then be missed.
Secondly, the duration of the wash-out period required
to clear all symptomatic effects of a given agent will gen-
erally not be known. Moreover, as exemplified by the
differing responses to levodopa withdrawal in patients
with PD (i.e. some deteriorate immediately whilst others
only deteriorate after several weeks), the required period
may vary considerably been individuals, making selection
of a long enough wash-out period very challenging. Ul-
timately, carry-over of symptomatic effects may occur if
the selected time is too short, and a disease-modifying
effect may erroneously be reported. It is notable that on
the whole the wash-out periods used in RCTs in PD
were shorter (median 6 (IQR 4 to 8) weeks) than in
those in AD (median 8 (IQR 6 to 12) weeks). This prob-
ably reflects the fact that, due to disabling motor symp-
toms, patients with PD are less able to stay off
symptomatic treatment for prolonged periods of time
than those with AD, rather than any considerations re-
lated to the pharmacokinetics of individual agents.
The problems of choosing too short a wash-out period
were illustrated in the DATATOP trial [26]. The wash-out
period of 4 to 8 weeks was inadequate because selegiline
irreversibly blocks monoamine oxidase B (MAO-B) and,
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therefore, its actions can only be overcome by forma-
tion of new enzyme in the brain, which has a 40 day
half-life [27].
Thirdly, from examining the RCTs included in this
systematic review it was readily apparent that there is no
consensus on how to analyse the wash-out period. In the
majority of RCTs the primary study analysis was con-
ducted from baseline until the start of the wash-out
period, before a separate wash-out analysis was then
conducted. In some studies this separate analysis only
entailed examining for a statistically significant deterior-
ation over the wash-out period in the active-agent
treated group, while in others a comparison was made
between the deterioration in both treatment groups dur-
ing the wash-out period. The approach in other RCTs
was simply to include the wash-out period in the pri-
mary outcome analysis: a difference in the change in pri-
mary outcome measures from the start of the study until
the end of the wash-out period was examined for. These
different methods of analysis make comparing the re-
sults of different studies extremely difficult.
Finally, in several included RCTs (e.g. in the PD RCT
by Tetrud and Langstone [28]) a wash-out analysis using
secondary outcome measures was inappropriately com-
bined with a primary outcome analysis of a time-to-
event outcome. This may mean that in some patients
the full symptomatic effect of the active-agent may not
have developed by the time the trial endpoint is reached.
Furthermore, the symptomatic effect of a given agent
may vary throughout the course of the disease which
makes interpretation of the results of such wash-out
analyses difficult. Combining a wash-out period with a
primary outcome related to the need for dopaminergic
treatment also risks some participants having to with-
draw prior to the wash-out period due to the urgent
need to commence symptomatic treatment. For ex-
ample, in one study [28] only 70 % (38/54) of rando-
mised subjects completed the wash-out period and 11 %
(6/54) withdrew from the study immediately prior to the
wash-out period or shortly thereafter.
Randomised delayed-start trial design
In studies with a delayed-start design [5] one group of
participants are randomised to receive the active-agent
from the beginning, while the rest are randomised to re-
ceive placebo initially and then the active-agent at a later
time point (delayed-start). In theory, if the putative agent
has a purely symptomatic effect then when the second
group receive the drug the progression curves for both
groups should meet. However, if the compound has a
purely disease-modifying effect then the progression
curve of the delayed-start group will never catch up with
those treated from the beginning as they will have bene-
fited from longer exposure to the drug’s disease-
modifying properties. In addition to comparing out-
comes between groups at the end of the study, a suf-
ficient number of follow-up assessments are required
to allow meaningful slope analyses. However, there
are several problems with the delayed-start design
which make drawing conclusions about an agent’s
disease-modifying properties on the results of such a
trial questionable [4, 5, 29].
Firstly, a positive result in favour of the early-
treatment group in a delayed-start trial may simply be
due to earlier symptomatic treatment preventing dele-
terious compensatory mechanisms rather than specific
disease modification [30].
Secondly, uncertainty exists as to how long the opti-
mal delay for keeping patients on placebo during a
delayed-started trial is. If it is too long then an unaccept-
ably high drop-out rate may be encountered. This may
lead to an imbalance in the treatment arms, selecting pa-
tients with slowly progressive disease who are able to
cope for longer without any treatment. On the other
hand, the treatment delay must be long enough to allow
differential disease progression between the treatment
arms to occur and for a given agent to reach its full
symptomatic effect.
Thirdly, whilst delayed-start trials are labelled as
double-blind this is perhaps only true for the first phase
of the study, where patients are randomised to either
placebo or active-agent [31]. Where the predetermined
duration of the first phase of the trial is publically avail-
able (e.g. on ClinicalTrials.gov or in patient information
leaflets), the second phase of the study may in essence
become an open-label study. Furthermore, a clinical re-
sponse to the active-agent in the second half of the study
in those initially treated with placebo may retrospectively
unblind these subjects. As clinical scoring at the end of
the study is crucial, unblinding may compromise the
overall study findings. It is possible to preserve blinding
by performing a second randomisation to the initial pla-
cebo group, so that a proportion of patients are main-
tained on placebo throughout the trial [32]. However,
this would result in an even more complicated study de-
sign and require a larger sample size.
Fourthly, how the results of a delayed-start trial should
be analysed and interpreted is not entirely clear. Several
features of a delayed-start trial can be analysed, includ-
ing the difference in outcome measures between groups
at the end of study, the difference in the rate of change
in outcome measures between groups during the first
and second phases of the study, and the size of any
symptomatic response observed in wash-in analyses at
the start of each study phase. How many of these ana-
lyses have to be ‘positive’ to prove disease-modification
has not been determined. Furthermore, uncertainty sur-
rounds how to deal with missing data in each phase of
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the study and how to appropriately power a delayed-
start trial [33].
All these issues are made even more complex by the
possibility that disease-modifying agents may have add-
itional symptomatic benefits, which can lead to incon-
clusive results. For example, false negative results may
occur if the symptomatic effect of the putative agent
overwhelms any disease-modifying effect. In the ADA-
GIO trial [21] the disease-modifying potential of the
MAO-B inhibitor rasagiline in PD was examined. ADA-
GIO essentially compromised two separate delayed-start
trials defined by two different doses of rasagiline (1 mg and
2 mg daily). However, only the group administered the
smaller dose for the full study period had significantly bet-
ter outcomes at the end of the study than its respective
delayed-start group. It is possible that an overwhelming
symptomatic effect of rasagiline in the 2 mg per day group
could account for this difference. Finally, a key assumption
of delayed-start designs - that the symptomatic response at
the beginning of the first and second phases are equal –
may well not be true as symptomatic responses may change
over time in conjunction with disease progression.
Long-term follow-up
Well-designed long-term follow-up trials, where disease-
modification is inferred from sustained divergence in
outcome measures between groups over time, may well
be the best current trial design to show disease modifica-
tion. However, they are time consuming and expensive
although their cost can be minimised by choosing out-
comes which can be collected from routine data (e.g. in
many countries mortality can be collected through na-
tional death registries). Uncertainty remains as to how
long follow-up study should be, although ultimately this
will depend on finding a balance between being suffi-
ciently long enough to allow disease-modification to be
demonstrated without unacceptably high rates of attri-
tion. Unfortunately, the potential of many long-term
follow-up studies included in this review to demonstrate
disease-modification was limited by the way their results
were analysed and the outcome measures employed.
Several such studies made no attempt to formally
examine for sustained divergence between treatment
arms and others only did so figuratively (e.g. by produ-
cing Kaplan Meier plots). In only one AD RCT was an
attempt made to undertake slope analyses to formally
demonstrate sustained divergence in outcome measures
between treatment groups over time [18]. Long-term
follow-up trials of anti-inflammatory agents in AD
(e.g. ibuprofen) generally only compared outcomes be-
tween treatment groups at the end of the study. This
relied on the assumption that such agents have no
symptomatic effect and, therefore, any difference be-
tween groups at the end of a RCT must be due to
disease-modification. This is quite a major assumption
to make if a therapeutic agent is to be labelled as
having disease-modifying properties. Future long-term
follow-up studies must not simply compare outcome
measures between groups at the end of the study but
also provide clear evidence of sustained divergence in
those outcome measures throughout the trial. The lat-
ter requires clinical assessments to be conducted at
several time points during the trial to enable a mean-
ingful slope analysis. Nonetheless, even slope analyses
have the potential to be misleading as they assume,
perhaps erroneously, linear progression of clinical out-
come measures, such as the UPDRS, as the disease
progresses [34]. An understanding of the change in
clinical outcome measures is, therefore, crucial.
Several long-term follow-up RCTs in PD used time-to-
event outcomes as the primary measure, which allows
censoring of missing data in survival analysis. The most
commonly used time-to-event outcome in PD was the
time until levodopa or dopaminergic treatment was re-
quired on the basis of individual patient’s level of disabil-
ity. Although this outcome was used as a surrogate for
disability it is rather subjective. The decision to com-
mence dopaminergic therapy depends on both patient
preference and on the clinical experience of the treat-
ing physician. Furthermore, the amount of symptom-
atic treatment taken varies greatly between individuals
(e.g. due to body weight, metabolism and levodopa
phobia). Time-to-event outcomes such as mortality or
reaching a specific level of clinical worsening, as used
in some AD RCTs, are less subjective. The main ad-
vantage of using time until dopaminergic treatment in
long-term follow-up studies in PD is clearly the
avoidance of the confounding effects of concomitant
symptomatic treatment. Perhaps a better solution is
to permit the commencement of symptomatic treat-
ment during a study when, and if, it is required and
adjust the results in accordance with the amount
taken.
Biomarkers
As our previous systematic reviews of biomarkers for
disease progression in AD [1] and PD [2] demonstrated,
there is currently insufficient evidence to support the
use of a biomarker as an outcome measure in RCTs in
either of these disorders. The use of biomarkers in sev-
eral of the included RCTs in combination with clinical
outcome measures and associated trial designs is, there-
fore, premature and potentially misleading. However,
with appropriate planning, the data required for bio-
marker validation (e.g. change in the biomarker over
time in comparison with clinical measures, feasibility of
measuring the biomarker and its acceptability to
patients) may be gained from RCTs by incorporating
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biomarkers. It did appear that this approach was being
followed in several of the included RCTs. It is also
important that biomarkers used as outcome measures
change in a manner congruent to the proposed thera-
peutic mechanism of action of the agent under inves-
tigation [35].
Missing data
Given that more than a quarter of participants in the in-
cluded RCTs in AD and PD failed to complete the
double-blind treatment periods in these trials, the results
of these studies may be confounded by missing data.
Missing data can result in several problems, including
unbalancing the treatment arms over time and introdu-
cing bias, both of which may lead to misleading infer-
ences being drawn. Moreover, missing data reduces the
overall efficacy of a study [36]. In the included RCTs a
variety of methods (complete-case analysis, LOCF, data
imputation, survival analysis and mixed models) were
used to deal with missing primary outcome data. Whilst
a detailed discussion of these methods is beyond the
scope of this article, we wish to make a few key points.
Any analyses conducted in a RCT should follow the
ITT principle [37], where patients are analysed accord-
ing to the groups they were initially randomised to.
Every patient who begins a trial should be considered to
be part of that trial regardless of whether or not they fin-
ish it. ITT is, therefore, a pragmatic approach to minim-
ise bias when estimating the effects of treatment
assignment in a RCT. However, a previous review of
RCTs published in major medical journals found that
less than half reported using the ITT approach and, of
those that did, this approach was often inadequately de-
scribed and inadequately applied [38]. In keeping with
these findings, only 36 (61 %) of the published RCTs in
AD and 19 (53 %) in PD stated that they applied an ITT
approach to their statistical analyses. Whilst in some
cases this may simply reflect an omission to specifically
state this, in others, where a complete-case analysis was
performed, the ITT principle was clearly broken.
Complete-case analysis, where only data from those who
complete a study is analysed, is an approach to dealing
with missing data that should be avoided. In RCTs in
neurodegenerative disorders, a complete-case analysis
can limit the generalisability of the study results to a mi-
nority of patients with slowly progressive disease who
are most likely to be able to complete a clinical trial.
LOCF analyses were frequently used in studies in-
cluded in this review to deal with missing data. For ex-
ample, in a trial by Shults et al., [39], the primary
outcome was the change in the total UPDRS over
16 months. To avoid confounding, symptomatic treat-
ment was prohibited and, therefore, those who required
dopaminergic treatment were withdrawn from the trial.
To avoid these individuals having missing data at the
final visit a LOCF analysis was performed. Final compar-
isons were, therefore, made between treatment groups
that contained a range of individuals with differing pe-
riods of follow-up. A LOCF analysis, such as this, risks
the difference between the groups at the predefined trial
endpoint being underestimated and, therefore, a signifi-
cant treatment effect being missed. Furthermore, if more
participants withdraw from one treatment group than
the other then a LOCF analysis may erroneously lead to
the conclusion that the former group performed better,
as LOCF effectively assumes that withdrawal from a
RCT halts disease progression.
A more sensible strategy would be to minimise miss-
ing data, for example by choosing a primary outcome
measure which is simple and easy to collect. Further-
more, many drop-outs could be avoided by permitting
the commencement of symptomatic therapy during a
trial, and adjusting the results on the basis of the
amount of symptomatic treatment taken. As already dis-
cussed, this approach would also have avoided many of
the PD long-term follow-up studies having to use ‘time-
to-symptomatic treatment’ as their primary outcome
measure.
Unfortunately, approaches to limit missing data are
unlikely to completely eliminate this problem and, there-
fore, measures to account for missing data are required.
Mixed modelling can be used to deal with missing data
in longitudinal datasets and allow the ITT approach to
data analysis to be maintained. These models take into
account patients who drop-out early when estimates for
later time points are made, but ensure that those with
missing data do not influence the results as greatly as
those with complete data. However, mixed modelling re-
lies on the assumption that missing data is ‘missing at
random’ (MAR) (e.g. due to an administrative error),
which is rarely the case in a RCT where data is generally
‘missing not at random’ (MNAR), often due to undocu-
mented disease progression. Sophisticated data imput-
ation methods, such as multiple imputation and
regression mean imputation, also assume that missing
data is MAR. The analysis of RCTs with MNAR data is
an extremely complex subject and a detailed discussion
of solutions to this problem is beyond the scope of this
article. However, it is worth noting that where assump-
tions are made to account for missing data then sensitiv-
ity analyses must be conducted to explore the effect of
departure from those assumptions on the main study
analysis [40].
Conclusion
Given the deficiencies we have described in each of the
design strategies previously used in RCTs in AD and PD,
and issues relating to the quantity of missing data in
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these trials and how this was dealt with, none of the
studies included in this review have definitively demon-
strated disease-modification. Currently, there does not
appear to be a clear alternative to long-term follow-up
trials which analyse for sustained divergence in outcome
measures between treatment arms over the time. Such
trials should aim to minimise missing data/drop-outs,
for example, by: allowing symptomatic treatment and
adjusting the results for the amount taken and choosing
a primary outcome measure which is simple and easy to
collect, for example death or dependency [41]. We also
recommend that any assumptions made to account for
missing data in the primary analysis should be tested in
sensitivity analyses.
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